GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » YoY Rev. per Sh. Growth

Oncternal Therapeutics (FRA:GTU) YoY Rev. per Sh. Growth : 0.00% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Oncternal Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2024 was 0.00%.

Oncternal Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was €0.00.


Oncternal Therapeutics YoY Rev. per Sh. Growth Historical Data

The historical data trend for Oncternal Therapeutics's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics YoY Rev. per Sh. Growth Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncternal Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oncternal Therapeutics YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Oncternal Therapeutics's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0-0)/ | 0 |
=N/A %

Oncternal Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Mar. 2024 )
=(Revenue per Share (Q: Mar. 2024 )-Revenue per Share (Q: Mar. 2023 )) / | Revenue per Share (Q: Mar. 2023 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncternal Therapeutics YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncternal Therapeutics (FRA:GTU) Business Description

Traded in Other Exchanges
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics (FRA:GTU) Headlines

No Headlines